Filing Details

Accession Number:
0001790300-21-000010
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-17 18:51:57
Reporting Period:
2021-07-22
Accepted Time:
2021-09-17 18:51:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1427570 Reshape Lifesciences Inc. RSLS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1181166 Thomas Stankovich 1001 Calle Amanecer
San Clemente CA 92673
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Per Share Acquisiton 2021-07-22 282,382 $0.00 315,995 No 4 A Direct
Common Stock, $0.001 Par Value Per Share Acquisiton 2021-07-22 90,362 $0.00 406,357 No 4 A Direct
Common Stock, $0.001 Par Value Per Share Disposition 2021-09-10 48,366 $2.89 357,991 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 S Direct
Footnotes
  1. These shares will vest and be issued with respect to 123,542 shares on July 22, 2021 and the remaining shares vesting monthly thereafter for 36 months pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
  2. These shares will vest and be issued monthly over 36 months beginning on July 22, 2021 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
  3. These shares were sold to cover taxes in connection with the vesting of restricted stock units.
  4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.88 to $2.90, inclusive. The Reporting Person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.